Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine with Trastuzumab and Vinorelbine in Metastatic Breast Cancer
NCT00266110Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2005
- Primary completion
- Feb 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of multiepitope autologous dendritic cell vaccine in breast cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of Participants With Response. Started Dec 2005; status: completed.
02
Drugs
multiepitope autologous dendritic cell vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00266110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266110.